About Covis Pharma
Covis Pharma is a Healthcare company based in Zug (Switzerland) founded in 2011, and was acquired by Azurity Pharmaceuticals in March 2025. Pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. The company has 10 employees. Covis Pharma has completed 1 acquisition, including AMAG Pharma. Covis Pharma offers products and services including Alvesco, Duaklir, Feraheme, and Tudorza. Its focus areas include Diversified Pharmaceuticals. Its legal entity is AMAG PHARMACEUTICALS INC.
Company details
Covis Pharma was founded in 2011 in Zug, Switzerland, as a pharmaceutical company focused on the sector of treatments for severe health issues. A portfolio of five products, including Altoprev, Betapace, Betapace AF, Rilutek for amyotrophic lateral sclerosis, and Lanoxin injection for moderate heart failure, is maintained. Operations involve marketing these therapies internationally. In April 2015, 18 products were acquired by Concordia Healthcare Group for 1.2 billion.
- Headquarters Zug, Switzerland
- Employees 10
- Stage Acquired
- SectorsHealthcare
- Website covispharma.com
- Social LinkedIn
- Acquired by Azurity Pharmaceuticals (Mar 2025)
- Legal Name Amag Pharmaceuticals Inc.
- Annual Revenue$474 M (USD)-4as on Dec 31, 2018
- Net Profit-$65.76 M (USD)67as on Dec 31, 2018
- EBITDA-$47.05 M (USD)85as on Dec 31, 2018
- Latest Funding Round$350M (USD), Debt – Conventional
Dec 2018
- InvestorsApollo Global Management
& 2 more
- Employee Count10
- Investments & Acquisitions
- Acquired by
Products & Services of Covis Pharma
Covis Pharma offers a comprehensive portfolio of products and services, including Alvesco, Duaklir, Feraheme, and Tudorza.
Treats asthma and respiratory conditions through inhalation therapy.
Manages chronic obstructive pulmonary disease symptoms effectively.
Provides iron treatment for anemia in chronic kidney disease patients.
Controls symptoms of chronic bronchitis and emphysema conditions.
Funding Insights of Covis Pharma
- Total Rounds 1
- Last Round Debt – Conventional — $350M
- First Round $350M
(Dec 2018)
All 1 funding rounds of Covis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $350M | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in Covis Pharma
Covis Pharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Apollo Global Management, Azurity Pharmaceuticals and Cerberus Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Buyouts are targeted through private equity investments by the firm. | 1990 | apollo.com | New York, United States | |
Private equity and debt firm focused on multiple sectors | cerberus.com | New York, United States | ||
Generic drugs are manufactured by Azurity Pharmaceuticals in the US. | 1999 | azurity.com | Woburn, United States |
Investor details for Covis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Covis Pharma
23 people are tracked at Covis Pharma (11 in leadership, 8 in board & advisors, 4 in team); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Amy Y. | Associate Director, Compliance (global) | Leadership |
Erin L.w. Owusu | Associate Director Clinical Operations | Leadership |
Ann Denardis-Tomcko | Director Supply And Trade | Leadership |
Yuriy Shveda | Associate Director, Market Access US | Leadership |
Ayman Noaman | Executive Director, Head Of European Business Operations | Leadership |
Michael Porter | Chief Executive Officer | Leadership |
Lenis de Leon | Associate Director Govn't Pricing & GTN Analytics | Leadership |
Ron Clark | General Manager | Leadership |
Susan Lucas | Executive Director Market Access, Pricing, Contracting, Trade And Government Affairs | Leadership |
Daniel Freedman | VP of Clinical Operations | Leadership |
Albert Dahouk | Chief Information Officer | Leadership |
Rolf Hoffman | Advisor | Board & advisors |
Sean E. Brynjelsen | Advisor | Board & advisors |
Dhinusha Munien | Director | Board & advisors |
Taavi Davies | Director | Board & advisors |
John J. Kiely | Advisor | Board & advisors |
Claude Noesen | Director | Board & advisors |
Alexis Heinen | Director | Board & advisors |
Lucas Ellend-Brown | Advisor | Board & advisors |
Duilia Jiménez | Customer Service And Process Improvement Manager | Team |
3 more people are available in the full profile.
Complete people profiles for Covis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Covis Pharma
Covis Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AMAG Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of anemia based products and imaging agents for cancer and CVD diagnosis | amagpharma.com | Waltham, United States | 1981 | Oct 2020 | •••• |
Complete acquisition details for Covis Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Covis Pharma
6 dated milestones of Covis Pharma across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Covis Pharma is founded.
- Exit Acquired by Cerberus Capital Management.
- Funding First funding round of $350.0M.
- Exit Acquired by Apollo Global Management.
- Acquisition Acquires AMAG Pharma.
- Exit Acquired by Azurity Pharmaceuticals.
Web traffic of Covis Pharma
The website of Covis Pharma (covispharma.com) receives about 5.4K visits a month.
- Monthly visits5.4K
▲ 58% vs previous month
Websites whose visitors overlap most with Covis Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
victoria-apotheke.ch | victoria-apotheke.ch | 100% | #3,106,880 | – | |
axapharm.ch | axapharm.ch | 85% | #2,806,905 | – | |
| santhera.com | 75% | 12.6K | #3,177,070 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Covis Pharma
Complete news archive for Covis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Covis Pharma
Covis Pharma was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Covis Pharma is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
Covis Pharma has 10 employees.
Annual revenue of Covis Pharma is $474M as on Dec 31, 2018.
Covis Pharma was founded in 2011 in Zug, Switzerland, as a pharmaceutical company focused on the sector of treatments for severe health issues. A portfolio of five products, including Altoprev, Betapace, Betapace AF, Rilutek for amyotrophic lateral sclerosis, and Lanoxin injection for moderate heart failure, is maintained. Operations involve marketing these therapies internationally. In April 2015, 18 products were acquired by Concordia Healthcare Group for 1.2 billion.
Covis Pharma offers Alvesco, Duaklir, Feraheme, and Tudorza.
Covis Pharma has made 1 acquisition, including AMAG Pharma.
Covis Pharma has 3 investors. Key investors include Apollo Global Management, Azurity Pharmaceuticals, and Cerberus Capital Management.
Covis Pharma operates through Amag Pharmaceuticals Inc..
Yes. Covis Pharma was acquired by Azurity Pharmaceuticals in March 2025.